Novo Nordisk Unveils Wegovy 7.2mg: New Strength for Enhanced Weight Loss
London, 14 January 2026 – Novo Nordisk has announced the approval of a new 7.2mg dose of Wegovy (semaglutide) in the UK, offering patients an advanced option for weight management. This higher strength, following successful clinical trials, aims to provide greater weight loss results for those who have plateaued on lower doses.
Introduction to Wegovy 7.2mg
Wegovy (semaglutide) is a prescription medication designed to support weight loss and long-term weight management in adults with obesity or overweight conditions. The active ingredient mimics the GLP-1 hormone, helping to regulate appetite, slow digestion, and control blood sugar levels. The new 7.2mg dose is administered weekly via prefilled pens and is intended for patients who have tolerated lower doses but require additional support.
Clinical Trials and Efficacy
The STEP UP trials, including STEP UP and STEP UP T2D, evaluated the 7.2mg dose in adults with obesity, with and without type 2 diabetes. Over 72 weeks, participants achieved an average weight loss of 20.7%, with one-third losing at least 25% of their body weight. This outperforms the 2.4mg dose, which yielded 17.5% average weight loss.
Key Facts and Comparisons
| Aspect | Wegovy 7.2mg | Wegovy 2.4mg | Mounjaro 15mg |
|---|---|---|---|
| Average Weight Loss (72 weeks) | 20.7% | 17.5% | 20.9% |
| Patients Losing ≥25% Body Weight | 33.2% | 16.7% | Similar high rates |
| Administration | Weekly injection (three 2.4mg pens) | Weekly injection | Weekly injection |
| Private UK Cost (Monthly) | £279 | £170–£300 | Similar to Wegovy 7.2mg |
Dosage and Administration
The 7.2mg dose is not a starting point; patients must titrate up from lower doses (0.25mg to 2.4mg) over 16 weeks. Currently, administer three 2.4mg injections weekly at the same time. A dedicated 7.2mg pen is expected soon. Rotate injection sites (abdomen, thigh, upper arm) and follow healthcare provider guidance.
Safety and Side Effects
Side effects are similar to lower doses, primarily gastrointestinal (nausea, diarrhoea, constipation). In trials, 5.4% discontinued due to side effects, compared to 4% on 2.4mg. Dysaesthesia (tingling) occurred in 23% but was mostly mild. Serious risks include pancreatitis and thyroid issues; consult a doctor if symptoms arise.
Eligibility and Access
Eligible patients have a BMI ≥30 or ≥27 with weight-related conditions, and have tolerated 2.4mg. Available privately in the UK from January 2026; NHS access pending NICE assessment. Costs range from £279 monthly privately.
Frequently Asked Questions
What is Wegovy 7.2mg?
Wegovy 7.2mg is the highest dose of semaglutide for weight loss, approved in the UK for patients needing more support beyond 2.4mg.
How effective is it?
Clinical trials show 20.7% average weight loss over 72 weeks, with 33.2% achieving ≥25% loss.
Who can take it?
Adults with obesity or overweight plus conditions, who have tolerated lower doses.
What are the side effects?
Common: nausea, diarrhoea, constipation. Rare: pancreatitis, allergic reactions.
How much does it cost?
£279 monthly privately; NHS availability expected later.